Skip to main content
SpringerLink
Log in

We Need More Data: Choosing the Optimal Treatment Strategy for Patients with Resectable Metachronous Resectable Colorectal Liver Metastases

  • Invited Commentary
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nassar A, Phelip JM, Goéré D et al (2020) What is the best therapeutic strategy for metachronousresectable colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy? A multidisciplinary inter-group survey. World J Surg. https://doi.org/10.1007/s00268-020-05837-z

    Article  PubMed  Google Scholar 

  2. Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J ClinOncol 24(13):2065–2072

    Article  CAS  Google Scholar 

  3. Khoo E, O’Neill S, Brown E, Wigmore SJ, Harrison EM (2016) Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB 18(6):485–493

    Article  Google Scholar 

  4. Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN (1999) Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 126(2):178–183

    Article  CAS  Google Scholar 

  5. El Saghir NS, Keating NL, Carlson RW, Khoury KE, Fallowfield L (2014) Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book: e461–466

  6. Benson AB, Venook AP, Al-Hawary MM et al (2018) NCCN guidelines insights: colon cancer, version 2.2018. J NatlCompr Cancer Network: JNCCN 16(4):359–369

    Article  Google Scholar 

  7. Bridgewater JA, Pugh SA, Maishman T et al (2020) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21(3):398–411

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Ohio State University Wexner Medical Center, 320 W. 10thAvenue, M-260 Starling Loving Hall, Columbus, OH, 43210, USA

    Aslam Ejaz & Timothy M. Pawlik

Authors
  1. Aslam Ejaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy M. Pawlik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aslam Ejaz.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ejaz, A., Pawlik, T.M. We Need More Data: Choosing the Optimal Treatment Strategy for Patients with Resectable Metachronous Resectable Colorectal Liver Metastases. World J Surg 45, 831–832 (2021). https://doi.org/10.1007/s00268-020-05894-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-020-05894-4

Search

Navigation